Nintedanib is an anti-angiogenesis anti-cancer agent. Nintedanib is an indolinone-derived drug that inhibits the process of blood vessel formation (angiogenesis)Nintedanib, marketed under the brand names Ofev and Vargatef, is an oral medication used for the treatment of idiopathic pulmonary fibrosis (IPF) and along with other medications for some types of non-small-cell lung cancer. Common side effects include abdominal pain, vomiting, and diarrhea. It is a small molecule tyrosine-kinase inhibitor, targeting vascular endothelial receptor (VEGFR), fibroblast receptor (FGFR) and platelet derived receptor (R). It was developed by Boehringer Ingelheim. At an assumed cost of 39,300 pounds per year it does not appear to be cost effective for IPF in the United Kingdom.
Application
Nintanib targets platelet-derived receptors (α and β), fibroblast receptors (FGFR1-3), vascular endothelial receptors (VEGFR1-3), and the adenosine triphosphate ( ATP) binding sites competitively bind, block the signal pathway of fibrosis process, inhibit the proliferation, metastasis and transformation of fibroblasts, thereby slowing the progression of IPF disease.
Complaint
